<SEC-DOCUMENT>0001415889-22-007061.txt : 20220629
<SEC-HEADER>0001415889-22-007061.hdr.sgml : 20220629
<ACCEPTANCE-DATETIME>20220629201112
ACCESSION NUMBER:		0001415889-22-007061
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220627
FILED AS OF DATE:		20220629
DATE AS OF CHANGE:		20220629

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Brazzell Romulus K
		CENTRAL INDEX KEY:			0001298079

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38150
		FILM NUMBER:		221056188

	MAIL ADDRESS:	
		STREET 1:		C/O INSPIRE PHARMACEUTICALS, INC.
		STREET 2:		4222 EMPEROR BLVD., SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703

	FORMER NAME:	
		FORMER CONFORMED NAME:	Brazzell Kim
		DATE OF NAME CHANGE:	20040722

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kala Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001479419
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				270604595
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1167 MASSACHUSETTS AVENUE
		CITY:			ARLINGTON
		STATE:			MA
		ZIP:			02476
		BUSINESS PHONE:		781-996-5252

	MAIL ADDRESS:	
		STREET 1:		1167 MASSACHUSETTS AVENUE
		CITY:			ARLINGTON
		STATE:			MA
		ZIP:			02476
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-06292022_050657.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-06-27</periodOfReport>

    <issuer>
        <issuerCik>0001479419</issuerCik>
        <issuerName>Kala Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>KALA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001298079</rptOwnerCik>
            <rptOwnerName>Brazzell Romulus K</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O KALA PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1167 MASSACHUSETTS AVENUE</rptOwnerStreet2>
            <rptOwnerCity>ARLINGTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02476</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>SEE REMARKS</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-06-27</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>3144</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.37</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>285201</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.</footnote>
        <footnote id="F2">Includes 58,834 unvested RSUs.</footnote>
    </footnotes>

    <remarks>Head of Research and Development and Chief Medical Officer</remarks>

    <ownerSignature>
        <signatureName>/s/ Mary Reumuth, Attorney-in-Fact</signatureName>
        <signatureDate>2022-06-29</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
